Digital trials: how artificial intelligence optimises phenotyping, recruitment, and adaptive designs in cardiometabolic therapeutics

31 August 2026 (14:30 - 14:45)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Steven Niederer

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail

Artificial intelligence-enabled target discovery: decoding cardiometabolic pathways from omics to mechanism

Doctor M. Kelm (Berlin, DE)

Presentation thumbnail

Regulatory science meets artificial intelligence: pathways for approval of artificial intelligence-developed cardiometabolic drugs

Professor P. Szymanski (Warszawa, PL)

Presentation thumbnail

Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval - discussion

Access the full session

Session thumbnail

Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval

The Event

Event poster

ESC Congress 2026

31 August 2026 14:30 CET

You may be interested in

Congress Presentation

Using artificial intelligence agents to run digital clinical trials within large registries: is this the future?

30 August 2026

Congress Presentation

Harnessing digital twins for cardiovascular research: a new frontier in precision medicine

22 November 2025

Congress Presentation

High-dimensional phenotypic matching with artificial intelligence-enhanced ECG to replicate heart failure trial outcomes in real-world data

29 August 2025

Congress Session

Digital innovations in clinical practice

31 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources